A gap between total prostate-specific antigen and the sum of free prostate-specific antigen plus α1-antichymotrypsin-prostate-specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasia

Clinical Chemistry

Volumn 45, Issue 3, 1999, Pages 422-424

  Jung, Klaus ^a   Brux, Brigitte ^a   Knäbich, Angela ^a   Lein, Michael ^a   Sinha, Pranav ^a   Schnorr, Dietmar ^a   Loening, Stefan A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; C REACTIVE PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; FINGER; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROTEIN PROTEIN INTERACTION; RECTUM; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL RESECTION;

EID: 0032941966     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.3.422     Document Type: Article

References (17)

1. 1. Catalona WJ. Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review. Prostate Suppl 1996;7:64-9.
2. 2. Van Iersel MP, Witjes WPJ, Thomas CMG, Segers MFG, Oosterhof GON, Debruyne FMJ. Review on the simultaneous determination of total prostate-specific antigen and free prostate-specific antigen. Prostate Suppl 1996;7: 48-57.
3. 1antichymotrypsin. Clin Chem 1991;37:1618-25.
4. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-6.
5. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5.
6. 6. Wu JT, Zhang P, Liu GH, Wilson L. Development of an immunoassay specific for the PSA-ACT complex without the problem of high background. J Clin Lab Anal 1998;12:14-9.
7. 7. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. Part I. J Clin Chem Clin Biochem 1983;21:709-20.
8. 8. Blijenberg BG, Kessler AC, Uhl W. Multicentre evaluation of a new fully automated enzyme immunoassay for total prostate-specific antigen. Eur J Clin Chem Clin Biochem 1995;33:965-73.
9. 9. Lein M, Koenig F, Jung K, McGovern FJ, Skates SJ, Schnorr D, Loening SA. Ratio of free prostate-specific antigen to total prostate-specific antigen in a population of 1160 healthy men. Br J Urol 1998;82:231-6.
10. 10. Stamey TA, Chen Z, Prestigiacomo AF. Reference material for PSA: the IFCC standardization study. Clin Biochem 1998;31:475-81.
11. 11. Christensson A, Lilja H. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 1994;220:45-53.
12. 1-protease inhibitor in vitro. Prostate 1997;33:87-96.
13. 1anti-chymotrypsin. Prostate 1995;27:166-75.
14. 14. Björk T, Piironen T, Pettersson K, Lövgren T, Stenman U-H, Oesterling JE, et al. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology 1996; 48:882-8.
15. 1-antichymotrypsin complex for the screening and management of prostate cancer. J Clin Lab Anal 1998;12:32-40.
16. 16. Wang TJ, Linton HJ, Payne J, Rittenhouse HG, Wolfert RL, Chan DW, et al. Clinical utility of a complexed PSA immunoassay with a specific monoclonal antibody to PSA-ACT [Abstract]. J Urol 1997;157:147.
17. 17. Allard WJ, Zhou Z, Yeung KK. Novel immunoassay for the measurement of complexed prostate specific antigen in serum. Clin Chem 1998;44:1216-23.